The Director, HCP Medical Education & Congress Strategy will develop and execute the U.S. KOL engagement strategy, medical education programming, peer-to-peer promotional activities, and congress commercial strategy for Admilparant across idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Admilparant is an investigational LPA1 antagonist and is not yet approved by the FDA. The role will shape how pre- and post-launch disease and product education reaches external stakeholders through thought leaders, scientific forums, and promotional and educational programs. The Director will build relationships, programs, and systems that support credible, compliant, and consistent engagement across the IPF/PPF HCP landscape, including pulmonologists, ILD centers, and multidisciplinary care teams. In partnership with Medical Affairs and the broader Admilparant HCP Marketing team, the role will identify and activate KOLs, lead annual congress strategy and execution, manage peer-to-peer and speaker bureau programs, and develop the operational infrastructure for KOL engagement ahead of launch. This is a launch-stage role requiring strong execution, accountability, and a compliance-first mindset. The Director will partner with Medical Affairs, Market Access, Commercial colleagues, Congress Management, and external agencies. Domestic travel of approximately 25% is expected.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director